Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of September 2019. The report details the presentation of new clinical data at the European Society for Medical Oncology (ESMO) Congress 2019 regarding GSK3359609, an investigational ICOS receptor agonist antibody.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report focused exclusively on clinical trial updates and does not contain financial statements.
Material Changes and Clinical Data
The primary material update concerns the INDUCE-1 study results for GSK3359609 in patients with head and neck squamous cell carcinoma (HNSCC):
- Combination Therapy: In 34 evaluable patients naive to PD-1/L1 therapy receiving GSK3359609 plus pembrolizumab, the overall response rate was 24% (n=8). Median progression-free survival was 5.6 months, with responses durable for 6 months or longer.
- Monotherapy: In 16 evaluable patients previously treated with PD-1/L1 therapy, the overall response rate was 6% (n=1).
- Safety: The safety and tolerability profile was consistent with prior dose escalation phases.
Guidance, Outlook, and Management Commentary
Management expressed encouragement regarding the potential of GSK3359609 to enhance anti-tumour activity beyond PD-1 blockade alone. Based on these results, GSK is initiating the INDUCE-3 registrational phase II/III trial to investigate survival benefits in first-line recurrent/metastatic HNSCC patients who are PD-L1 positive. This trial is expected to begin by the end of 2019 in collaboration with Merck & Co, Inc. (MSD).
Risks and Contingencies: The filing includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties, including those described in the company's 2018 Annual Report on Form 20-F. GSK3359609 is not currently approved for use anywhere in the world.
Key Facts for Investor Verification
- Verification of the initiation timeline for the INDUCE-3 registrational trial (targeted for end of 2019).
- Confirmation of the ongoing collaboration agreement with Merck & Co, Inc. regarding the combination trial.
- Monitoring of future safety data and long-term survival outcomes from the INDUCE-1 expansion phase.
- Assessment of the impact of this oncology pipeline progress on GSK's broader immuno-oncology strategy.